Pharma industry makes a request to MOTIE and MOEF

By Nho, Byung Chul | translator Kim, Jung-Ju

23.03.22 05:50:53

가나다라 0

Economic Regulatory Innovation TF plans to review the request and closely discuss the issue with MOTIE

Toxin preparations, lack originality and progressive superiority...should allow free trade

Terrorism through chemical weaponry of botulinum toxin is virtually impossible...industry eyes on whether authorities will cancel national core technology designation

Public opinion has been rising for the government to revoke the designation of botulinum toxin as a national core technology.

The rise of this public opinion brings more meaning as the request was made by Korea Pharmaceutical and Bio-Pharma Manufacturers Association, which represents the industry. Breaking away from lesser movements that had been made by individual companies or internally within the Ministry of Trade, Industry, and Energy, KPBMA has taken entitative and requested the above for industry development and the future.

According to industry sources, KPBMA sent an opinion statement last week requesting the MOTIE to revoke the national core technology designation it had set fo

Nho, Byung Chul(sasiman@dailypharm.com)

If you want to see the full article, please JOIN US (click)